Stocks · News reference
Artelo Biosciences Says First Patient Dosed In DREAM Study Evaluating Effects Of ART27.13 In Patients With Glaucoma Or Ocular Hypertension; Initial DREAM Study Results Anticipated In Q4
Investigator-led study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmologyInitial DREAM Study Results Anticipated in Q4 2026SOLANA BEACH, Calif., Aug. 10, 2026
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Artelo Biosciences shares are trading lower after the company announced a 1-for-9 reverse stock split.
8-K filing — ARTELO BIOSCIENCES, INC. (ARTL)
Filed: 2026-08-27 AccNo: 0001640334-26-001421 Size: 721 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits